• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Patrick T. McGann, MD, MS

Associate Professor
UC Department of Pediatrics
Cincinnati Children's Hospital Medical Center
3333 Burnet Avenue
Cincinnati, Ohio, United States

Dr. McGann was a leader in the development of a newborn screening and treatment program in the Republic of Angola. Toward this end, he worked and lived in Angola for much of two and a half years. This work helped to develop many relationships and is the foundation for much of his continued research and public health efforts in Angola. His research efforts during this time were supplemented by formal training in clinical research through the American Society of Hematology’s Clinical Research Training Institute and through the master’s program in clinical research at Baylor College of Medicine.

He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP’s al Child Health (SOICH). Upon arrival to Cincinnati Children’s, Dr. McGann was the recipient of the Procter Scholar Award, which will help to support his international research efforts.

Grants: A Phase I/II Study of Hydroxyurea for Children with Sickle Cell Anemia in Angola. Principal Investigator. Procter Scholar Award, Cincinnanti Children’s Hospital Medical Center TAPS Program. Jan 2014-Dec 2016. Sickle Cell Education and Screening for Angolan Adolescents. Co-Director/Mentor. AAP International Community Access to Child Health (ICATCH). Jan 2014-Dec 2016.  


Representative Publications:

The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies

Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples

Time to Invest in Sickle Cell Anemia as a Global Health Priority

Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia

Hydroxyurea therapy for sickle cell anemia

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.